Evidence map›Paper›PMID 42262888›Full record

ArticleThe Journal of clinical investigation2026

APOL1 risk alleles modulate T cell receptor signaling to promote allograft rejection.

John Pell, E M Tanvir, Zeguo Sun, Irene Chernova, Anand Reghuvaran, Soichiro Nagata, Mateus T Guerra, John Choi, Soltan Al Chaar, Hiroki Mizuno and 24 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

John PellSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
E M TanvirSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Zeguo SunDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Irene ChernovaSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Anand ReghuvaranSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Soichiro NagataSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Mateus T GuerraSection of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
John ChoiTransplant Research Center, Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Soltan Al ChaarTransplant Research Center, Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Hiroki MizunoTransplant Research Center, Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ke DongSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Xin TianSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Reika IshibeSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Barbara FranchinDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Paolo CravediDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ashwani KumarSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Gabriel BarsottiSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Hongmei ShiSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Bony De KumarSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Shinobu SmithsonDivision of Nephrology, Washington University, St. Louis, Missouri, USA.
Wenzhi SongSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
John Cijiang HeDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Anita S ChongDepartment of Surgery, The University of Chicago, Chicago, Illinois, USA.
Jordan S PoberDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Stefan SomloSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Ian W GibsonDepartment of Pathology, University of Manitoba, Winnipeg, Manitoba, Canada.
Waldemar PopikCenter for AIDS Health Disparities Research, Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee, USA.
Zhongyang ZhangDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Joseph CraftDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Jamil AzziTransplant Research Center, Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Naoka MurakamiTransplant Research Center, Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Shuta IshibeSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.
Peter S HeegerCedars-Sinai Medical Center, Los Angeles, California, USA.
Madhav C MenonSection of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.

Funding

Dichotomous roles of Shroom3 in Tubular cells and Podocytes in native and allograft kidneysR01DK122164 · NIDDK · YALE UNIVERSITY · PI Madhav C Menon · 2019 to 2026
$2.7M
Human and Translational Immunology Training ProgramT32AI155387 · NIAID · YALE UNIVERSITY · PI Joseph Edgar Craft, Kevan C Herold · 2021 to 2026
$2.6M
Role of AMP-kinase pathway in the regulation of Minimal change disease-to-FSGS transitionR01DK132274 · NIDDK · YALE UNIVERSITY · PI Madhav C Menon · 2023 to 2026
$2.1M
Modelling mechanisms of progressive chronic kidney disease in APOL1 high-risk live-donors using BAC-Transgenic miceR21AI178705 · NIAID · YALE UNIVERSITY · PI ISHIBE, SHUTA, MENON, MADHAV C · 2023 to 2024
$461k
NIAID NIH HHS R21 AI178705NIAID NIH HHS T32 AI155387NIDDK NIH HHS R01 DK122164NIDDK NIH HHS R01 DK132274
6 · The paper itself

Abstract

The exonic variants G1 and G2 in apolipoprotein-L1 (APOL1) are linked to an increased risk of kidney disease as well as kidney transplant rejection. Outside of the association of these prevalent variants with African ancestry, the underpinning causal mechanisms for rejection are unknown. We investigated T cell function using transgenic mice with physiologic expression of WT (G0), G1 APOL1 (G1), or G2 APOL1 (G2). Mice with the G1 or G2 variant showed greater CD8+ T cell activation with expansion of a central memory T cell (Tcm) subset. Stimulated G1 CD8+ T cells showed enhanced proliferation and cytokine production, which was reversed with APOL1 inhibition. In MHC-mismatched cardiac transplants, G1 mice demonstrated greater CD8+ T cell infiltration and worse survival. The bulk transcriptome of G1 CD8+ T cells and the single-cell transcriptome of graft-infiltrating Tcms showed enrichment of canonical T cell receptor (TCR) pathways including Ca2+ signaling. G1 CD8+ T cells demonstrated baseline ER Ca2+ depletion followed by sustained increases in cytosolic Ca2+ upon TCR stimulation. G1 CD8+ T cells were more sensitive to Ca2+ chelation, or store-operated Ca2+ entry inhibition, and were relatively resistant to calcineurin antagonism compared with G0 CD8+ T cells. Analogously, in a kidney transplant cohort, transplant recipients carrying an APOL1 risk variant (G1 or G2) who had elevated peripheral Tcms before transplantation developed rejection despite having significantly higher tacrolimus levels than recipients with the G0/G0 APOL1 genotype. In summary, we have unraveled an excitatory mechanism for APOL1 variants in T cells that causally links them to kidney rejection.

Indexed as

AllelesApolipoprotein L1Calcium SignalingCD8-Positive T-LymphocytesGraft RejectionHeart TransplantationReceptors, Antigen, T-CellSignal TransductionAllograftsAnimalsHumansMaleMiceMice, TransgenicAPOL1 protein, humanApolipoprotein L1Receptors, Antigen, T-CellImmunologyNephrologyTransplantation

Identifiers

PMID42262888
PMCPMC13430025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.